Promising
AHK-Cu (Copper Tripeptide)
The prediction game
Call it: rising or fading?
Where does AHK-Cu (Copper Tripeptide) stand 12 months from now? Lock your call with a confidence level. When the window closes, the Brier rule scores your calibration: right and confident earns the most, wrong and confident costs the most. Points and a leaderboard spot are the whole prize. No stakes, no money.
One call per intervention. It locks the moment you submit: no edits, no cancels. It resolves when the 12-month window closes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Community Signal
No weigh-ins yet. Be the first and set the early signal.
Evidence
Evidence grade: C (mixed evidence)
Graded from the strength of the published research, independent of any verdict on this page.
Evidence Anchor
BioHarmony 6.5/10
AHK-Cu sits at Neutral because it pairs a plausible mechanism and a clean safety profile with an almost empty human-evidence file. The practical verdict: it is a reasonable, low-risk add-on to a real hair protocol if you go in expecting little, but it is a poor standalone bet and an easy thing to skip in favor of better-supported options. The single AHK-Cu study is in-vitro and ex-vivo from 2007, with no human trial and no replication, per Pyo 2007, so any clinically proven hair growth claim is unsupported for this specific peptide. The two things to keep straight are the naming confusion with GHK-Cu and DAHK, and the off-label injectable use you should avoid. ✅ Best for: People who already run a proven hair protocol, like minoxidil, and want a cheap, low-risk topical to layer on without high expectations. Tinkerers who accept that AHK-Cu rests on a single dish study and are fine experimenting on that basis. Anyone drawn to copper peptides who understands that GHK-Cu is the better-evidenced cousin and is choosing AHK with eyes open. People who value a trivially reversible cosmetic they can stop anytime. Readers who want to understand the naming traps before they shop, since the Copper Tripeptide-1 versus Copper Tripeptide-3 confusion drives a lot of bad marketing, per Wang 2021. ❌ Avoid if: You want an evidence-backed standalone hair-loss treatment, because AHK-Cu has no human trial and minoxidil is the only FDA-approved topical. You would skip the better-studied GHK-Cu to use it, since GHK has the deeper record, per Pickart 2008. You are tempted by gray-market injectable or mesotherapy use, which is off-label, non-approved, and unstudied for AHK-Cu and bypasses the only barrier it was ever tested across. You have a known sensitivity to copper-peptide cosmetics or active scalp irritation. You are relying on product claims rather than the actual evidence, since many serums blend AHK with other actives and you cannot credit any result to AHK-Cu alone, per Liu 2020.
Read the full BioHarmony report
My score and my verdict: one signal of three, never the whole answer.
Momentum
Signals begin with Edition 2
Direction needs two weekly snapshots to compare, so the arrows stay off until the next edition. Attention tracking is already running.
Momentum = how fast attention is rising across search, Reddit, PubMed, podcasts, and curated industry newsletters this week; it can flag an item as Overhyped/Fading, but it never overrides the evidence behind Proven. How momentum works.
- Ring
- Promising
- Trend
- Begins with Edition 2
- Momentum
- 0.0%
- BioHarmony Score
- 6.5/10
- Last Updated
- Jul 2, 2026
Sources
- BioHarmony score
- Search trend delta
- Reddit velocity
- PubMed publication count
- Podcast mention frequency
- Curated newsletter mentions
The score anchors the ring; the other five drive momentum, which can nudge the ring by one step at most. How placement works.
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.